Skip to content

Psychedelic Effects of Ketamine in Healthy Volunteers

Andrew t. Bowdle, Allen d. Radant, Deborah s. Cowley, Evan d. Kharasch, Rick j. Strassman, Peter p. Roy-Byrne

Anesthesiology 1998 DOI: 10.1097/00000542-199801000-00015 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Single-blinded crossover protocol Peer reviewed
Sample size 10
Population Psychiatrically healthy volunteers
Intervention Ketamine
Dose 0, 50, 100, 150, and 200 ng/ml target plasma concentrations
Duration 30 min per concentration step, with assessments after 20 min at each step; one hour after infusion discontinuation
Topics Esketamine Ketamine
Keywords Ketamine ketamine levels Ketamine concentrations Potent psychedelic compounds Dose-response relationship direct Linear relationship Intensity of effects Specific ketamine levels Predictable alterations Dosage Human study researchers Volunteers Work Carefully measured
Citations 371
Key points Subanesthetic doses of ketamine produce dose-related psychedelic effects, with a highly linear relationship between steady-state plasma concentrations and effect intensity between 50 and 200 ng/ml.

Abstract

Background: Ketamine has been associated with a unique spectrum of subjective "psychedelic" effects in patients emerging from anesthesia. This study quantified these effects of ketamine and related them to steady-state plasma concentrations.

Methods: Ketamine or saline was administered in a single-blinded crossover protocol to 10 psychiatrically healthy volunteers using computer-assisted continuous infusion. A stepwise series of target plasma concentrations, 0, 50, 100, 150, and 200 ng/ml were maintained for 30 min each. After 20 min at each step, the volunteers completed a visual analog (VAS) rating of 13 symptom scales. Peripheral venous plasma ketamine concentrations were determined after 28 min at each step. One hour after discontinuation of the infusion, a psychological inventory, the hallucinogen rating scale, was completed.

Results: The relation of mean ketamine plasma concentrations to the target concentrations was highly linear, with a correlation coefficient of R = 0.997 (P = 0.0027). Ketamine produced dose-related psychedelic effects. The relation between steady-state ketamine plasma concentration and VAS scores was highly linear for all VAS items, with linear regression coefficients ranging from R = 0.93 to 0.99 (P < 0.024 to P < 0.0005). Hallucinogen rating scale scores were similar to those found in a previous study with psychedelic doses of N,N-dimethyltryptamine, an illicit LSD-25-like drug.

Conclusions: Subanesthetic doses of ketamine produce psychedelic effects in healthy volunteers. The relation between steady-state venous plasma ketamine concentrations and effects is highly linear between 50 and 200 ng/ml.

Comparable studies

Other randomized controlled trials on ketamine, most cited first.

Study Year Design Participants
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Healthy human subjects recruited from the community 1994 Randomized controlled trial n = 19
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial Patients with treatment-resistant major depression experiencing a major depressive episode 2013 Randomized controlled trial n = 73
Remifentanil-induced Postoperative Hyperalgesia and Its Prevention with Small-dose Ketamine Patients undergoing major abdominal surgery 2005 Randomized controlled trial n = 75
Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder Patients with chronic PTSD related to a range of trauma exposures 2014 Randomized controlled trial n = 41
Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers Healthy volunteers 2000 Single-blind placebo-controlled study n = 20

Citations in the library

Explore topics